Read the full story by clicking on this headline.. |
The U.S. health regulator's staff reviewers on Wednesday raised a string of concerns with Intercept Pharmaceuticals' treatment for a type of fatty liver disease, sending the drugmaker's shares plunging 22%. The U.S. Food and Drug Administration's reviewers flagged increased... |
0 Comments
Leave a Reply. |
NewsMaxA conservative American news and opinion website founded by Christopher Ruddy in 1998 & operated by Newsmax Media. Archives
June 2023
Categories |